Electrochemical sensor based on reduced graphene oxide paste electrode for detection of gemcitabine as a chemotherapy drug in breast cancer

The development of a precise and sensitive electrochemical sensor is essential in the field of medical diagnostics in order to identify gemcitabine, a chemotherapy drug that is commonly used to treat breast cancer. This work presents a novel electrochemical sensor based on a reduced graphene oxide (rGO) nanocomposite and a zirconium-based metal-organic framework (Zr-MOF) with terephthalic acid as a ligand. Gemcitabine (GEM), a chemotherapy medication used to treat breast cancer, is detected with remarkable sensitivity and selectivity by the Zr-MOF-rGO modified graphene paste electrode (GrPE) sensor. By combining the strong structure and active sites of Zr-MOF with the large surface area and electrical conductivity of rGO, the sensor's design maximizes electron transfer rates and GEM adsorption capacity. The sensor outperforms current GEM sensors with its wide linear detection range (0.5–490 μM) and low detection limit (0.008 μM). The sensor's long-term analytical applicability is confirmed by stability and reusability studies, which produced accuracy rates surpassing 94 % and RSD values below 4.21 % in recovery trials using spiked human blood serum and urine samples. Overall, the results of this investigation show that the Zr-MOF-rGO/GrPE electrode has the potential to be a useful platform for the detection of gemcitabine in patients with breast cancer.